Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
February 8, 2017 7:34 AM EST
Jefferies analyst, Brandon Couillard, reiterated his Hold rating on shares of Myriad Genetics (NASDAQ: MYGN) even though MYGN posted its biggest revenue beat in >2 yrs. The analyst higlighted the evidence of stability in its flagship hereditary cancer (HC) unit, which grew sequentially (+3%), reversing... More
February 8, 2017 6:42 AM EST
Ladenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $15.40 yesterday.
...
More
February 7, 2017 4:28 PM EST
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of... More
